MARKET

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

0.9577
-0.0122
-1.26%
After Hours: 0.9401 -0.0176 -1.84% 16:33 10/22 EDT
OPEN
0.9651
PREV CLOSE
0.9699
HIGH
0.9900
LOW
0.9312
VOLUME
178.24K
TURNOVER
--
52 WEEK HIGH
1.997
52 WEEK LOW
0.6600
MARKET CAP
143.31M
P/E (TTM)
3.592
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of LCTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

LCTX News

  • Lineage Cell Therapeutics to Present at Dawson James Securities 5th Annual Small Cap Growth Conference on October 29, 2019
  • Business Wire.14h ago
  • Lineage Cell Therapeutics Highlights Presentation Of New OpRegen Data At American Academy Of Ophthalmology Annual Meeting
  • Benzinga.10/14 17:47
  • Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting
  • Business Wire.10/14 17:45
  • 4 Stocks To Watch For October 14, 2019
  • Benzinga.10/14 07:51

More

Industry

Biotechnology & Medical Research
+0.44%
Pharmaceuticals & Medical Research
+0.60%

Hot Stocks

Name
Price
%Change

About LCTX

Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).
More

Webull offers Lineage Cell Therapeutics Inc (LCTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.